References
- Powell SM, Zilz N, Beazer-Barclay Y et al. APC mutations occur early during colorectal tumorigenesis. Nature359(6392), 235–237 (1992).
- Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer9(7), 463–475 (2009).
- Dahabreh IJ, Linardou H, Siannis F, Fountzilas G, Murray S. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist13(6), 620–630 (2008).
- Roukos DH. Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann. Surg. Oncol.17, 14–17 (2010).
- Stafford RS, Wagner TH, Lavori PW. New, but not improved? Incorporating comparative-effectiveness information into FDA labeling. N. Engl. J. Med.361(13), 1230–1233 (2009).
- Bergh J. Quo vadis with targeted drugs in the 21stcentury? J. Clin. Oncol.27(1), 2–5 (2009).
- Roukos DH. Mea culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Rev. Mol. Diagn.9(3), 217–221 (2009).
- Gandara DR, Gumerlock PH. Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out? J. Clin. Oncol.23(25), 5856–5858 (2005).
- Peterson RT. Drug discovery: propping up a destructive regime. Nature461(7264), 599–600 (2009).
- Huang SM, Mishina YM, Liu S et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature461(7264), 614–620 (2009).
- Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N. Engl. J. Med.352(5), 476–487 (2005).
- Sargent D, Sobrero A, Grothey A et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J. Clin. Oncol.27(6), 872–877 (2009).
- Van Cutsem E, Köhne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med.360(14), 1408–1417 (2009).
- Tol J, Koopman M, Cats A et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med.360(6), 563–572 (2009).
- Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med.359(17), 1757–1765 (2008).
- Hecht JR, Mitchell E, Chidiac T et al. A randomized Phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol.27(5), 672–680 (2009).
- Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol.27(5), 663–671 (2009).
- Bastiaens P. Systems biology: when it is time to die. Nature459(7245), 334–335 (2009).
- Roukos DH, Tzakos A, Zografos G. Current concerns and challenges towards tailored anti-angiogenic therapy in cancer. Expert Rev. Anticancer Ther.9(10), 1413–1416 (2009).
- The human genome at ten. Nature464(7289), 649–650 (2010).
- Check Hayden E. Human genome at ten: life is complicated. Nature464(7289), 664–667 (2010).
- Human genome at ten: the sequence explosion. Nature464(7289), 670–671 (2010).
- Ledford H. Big science: the cancer genome challenge. Nature464(7291), 972–974 (2010).
- Collins F. Has the revolution arrived? Nature464(7289), 674–675 (2010).
- Venter JC. Multiple personal genomes await. Nature464(7289), 676–677 (2010).
- Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature458(7239), 719–724 (2009).
- Stephens PJ, McBride DJ, Lin ML et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature462(7276), 1005–1010 (2009).
- Beroukhim R, Mermel CH, Porter D et al. The landscape of somatic copy-number alteration across human cancers. Nature463(7283), 899–905 (2010).
- Hanahan D, Weinberg RA. The hallmarks of cancer. Cell100, 57–70 (2000).
- Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat. Rev. Cancer2(5), 331–341 (2002).
- Roukos DH. Systems medicine: a real approach for future personalized oncology? Pharmacogenomics11(3), 283–287 (2010).
- Schadt EE. Molecular networks as sensors and drivers of common human diseases. Nature461(7261), 218–223 (2009).
- Rockman MV. Reverse engineering the genotype–phenotype map with natural genetic variation. Nature456, 738–744 (2008).
- Wood LD, Parsons DW, Jones S. The genomic landscapes of human breast and colorectal cancers. Science318(5853), 1108–1113 (2007).
- Roukos DH. Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev. Mol. Diagn.10(3), 247–250 (2010).
- Roukos DH. Novel clinico-genome network modeling for revolutionizing genotype–phenotype-based personalized cancer care. Expert Rev. Mol. Diagn.10(1), 33–48 (2010).
Websites
- NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) www.nccn.org/professionals/physician_gls/f_guidelines.asp